11 results on '"Guillot, Loïc"'
Search Results
2. Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis
- Author
-
Mésinèle, Julie, Ruffin, Manon, Kemgang, Astrid, Guillot, Loïc, Boëlle, Pierre-Yves, and Corvol, Harriet
- Published
- 2022
- Full Text
- View/download PDF
3. FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition
- Author
-
Corvol, Harriet, Rousselet, Nathalie, Thompson, Kristin E., Berdah, Laura, Cottin, Guillaume, Foussigniere, Tobias, Longchampt, Elisabeth, Fiette, Laurence, Sage, Edouard, Prunier, Céline, Drumm, Mitchell, Hodges, Craig A., Boëlle, Pierre-Yves, and Guillot, Loic
- Published
- 2018
- Full Text
- View/download PDF
4. Translating the genetics of cystic fibrosis to personalized medicine.
- Author
-
Corvol, Harriet, Thompson, Kristin E., Tabary, Olivier, le Rouzic, Philippe, and Guillot, Loïc
- Abstract
Cystic fibrosis (CF) is the most common life-threatening recessive genetic disease in the Caucasian population. This multiorgan disease is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein, a chloride channel recognized as regulating several apical ion channels. The gene mutations result either in the lack of the protein at the apical surface or in an improperly functioning protein. Morbidity and mortality because of the mutation of CFTR are mainly attributable to lung disease resulting from chronic infection and inflammation. Since its discovery as the causative gene in 1989, much progress has been achieved not only in clinical genetics but also in basic science studies. Recently, combinations of these efforts have been successfully translated into development and availability for patients of new therapies targeting specific CFTR mutations to correct the CFTR at the protein level. Current technologies such as next gene sequencing and novel genomic editing tools may offer new strategies to identify new CFTR variants and modifier genes, and to correct CFTR to pursue personalized medicine, which is already developed in some patient subsets. Personalized medicine or P4 medicine ("personalized," "predictive," "preventive," and "participatory") is currently booming for CF. The various current and future challenges of personalized medicine as they apply to the issues faced in CF are discussed in this review. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Alveolar epithelial cells: Master regulators of lung homeostasis.
- Author
-
Guillot, Loïc, Nathan, Nadia, Tabary, Olivier, Thouvenin, Guillaume, Le Rouzic, Philippe, Corvol, Harriet, Amselem, Serge, and Clement, Annick
- Subjects
- *
EPITHELIAL cells , *LUNG physiology , *HOMEOSTASIS , *PROGENITOR cells , *PULMONARY gas exchange , *PNEUMONIA - Abstract
Abstract: The lung interfaces with the environment across a continuous epithelium composed of various cell types along the proximal and distal airways. At the alveolar structure level, the epithelium, which is composed of type I and type II alveolar epithelial cells, represents a critical component of lung homeostasis. Indeed, its fundamental role is to provide an extensive surface for gas exchange. Additional functions that act to preserve the capacity for such unique gas transfer have been progressively identified. The alveolar epithelium represents a physical barrier that protects from environmental insults by segregating inhaled foreign agents and regulating water and ions transport, thereby contributing to the maintenance of alveolar surface fluid balance. The homeostatic role of alveolar epithelium relies on the regulated/controlled production of the pulmonary surfactant, which is not only a key determinant of alveolar mechanical stability but also a complex structure that participates in the cross-talk between local cells and the lung immune and inflammatory response. In regard to these critical functions, a major point is the maintenance of alveolar surface integrity, which relies on the renewal capacity of type II alveolar epithelial cells, and the contribution of progenitor populations within the lung. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
6. Macrolides: New therapeutic perspectives in lung diseases
- Author
-
Guillot, Loïc, Tabary, Olivier, Nathan, Nadia, Corvol, Harriet, and Clement, Annick
- Subjects
- *
MACROLIDE antibiotics , *LUNG disease treatment , *TREATMENT effectiveness , *IMMUNOREGULATION , *PULMONARY fibrosis , *REGENERATION (Biology) , *HOMEOSTASIS , *SURFACE active agents - Abstract
Abstract: There is strong clinical evidence for the effectiveness of macrolides in the treatment of a number of chronic airway diseases through their immunomodulatory effects. Recently, new information has been released supporting the view that macrolides may also be beneficial in pathologic situations associated with altered repair of the alveolar structure, such as those observed in interstitial lung diseases and fibrosis. It is proposed that macrolides may contribute to lung regeneration through their actions on several components of the remodeling process. The present review provides new insights on the effects of macrolides on the regenerative response of alveolar epithelium to injury. It also discusses novel findings which suggest that macrolides may contribute to alveolar surfactant homeostasis. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus.
- Author
-
Guillot, Loïc, Le Goffic, Ronan, Bloch, Sarah, Escriou, Nicolas, Akira, Shizuo, Chignard, Michel, and Si-Tahar, Mustapha
- Subjects
- *
LUNGS , *EPITHELIAL cells , *IMMUNE response , *INFLUENZA viruses , *RNA , *INFLUENZA - Abstract
Influenza A is a highly contagious single-stranded RNA virus that infects both the upper and lower respiratory tracts of humans. The host innate immune Toll-like receptor (TLR) 3 was shown previously in cells of myeloid origin to recognize the viral replicative, intermediate double-stranded RNA (dsRNA). Thus, dsRNA may be critical for the outcome of the infection. Here we first compared the activation triggered by either influenza A virus or dsRNA in pulmonary epithelial cells. We established that TLR3 is constitutively expressed in human alveolar and bronchial epithelial cells, and we describe its intracellular localization. Expression of TLR3 was positively regulated by the influenza A virus and by dsRNA but not by other inflammatory mediators, including bacterial lipopolysaccharide, the cytokines tumor necrosis factor-α and interleukin (IL)-1β, and the protein kinase C activator phorbol 12-myristate 13-acetate. We also demonstrated that TLR3 contributes directly to the immune response of respiratory epithelial cells to influenza A virus and dsRNA, and we propose a molecular mechanism by which these stimuli induce epithelial cell activation. This model involves mitogen-activated protein kinases, phosphatidylinositol 3-kinase/Akt signaling, and the TLR3-associated adaptor molecule TRIF but not MyD88-dependent activation of the transcription factors NF-κB or interferon regulatory factor/interferon-sensitive response-element pathways. Ultimately, this signal transduction elicits an epithelial response that includes the secretion of the cytokines IL-8, IL-6, RANTES (regulated on activation normal T cell expressed and secreted), and interferon-β and the up-regulation of the major adhesion molecule ICAM-1. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
8. Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways.
- Author
-
Guillot, Loïc, Medjanes, Samir, Le-Barillec, Karine, Balloy, Viviane, Danel, Claire, Chignard, Michel, and Si-Tahar, Mustapha
- Subjects
- *
EPITHELIAL cells , *ENDOTOXINS , *IMMUNE response , *POLYMERASE chain reaction , *FLOW cytometry , *INTERLEUKINS - Abstract
Pulmonary epithelial cells are continuously exposed to microbial challenges as a result of breathing. It is recognized that immune myeloid cells express Toll-like receptors (TLRs), which play a major role in detecting microbes and initiating innate immune responses. In contrast, little is known concerning the expression of TLR in pulmonary epithelial cells per se, their distribution within the cell, their function, and the signaling pathways involved. In this work, we demonstrated by reverse transcription-PCR and/or immunoblot that TLR4 and the accessory molecule MD-2 are constitutively expressed in distinct human alveolar and bronchial epithelial cells. We further characterized by flow cytometry, biotinylation/precipitation, and confocal microscopy the intracellular localization of TLR4 in these cells. Despite this intracellular compartmentalization of TLR4, pulmonary epithelial cells were responsive to the TLR4 activator lipopolysaccharide (LPS), a potent Gram-negative bacteria-associated molecular pattern. Using respiratory epithelial cells isolated from TLR4 knock-out and wild type mice, we demonstrated that TLR4 is the actual activating receptor for LPS in these cells. Furthermore we showed that this cell response to LPS involves a signaling complex including the kinases interleukin-1 receptor-associated kinase (IRAK), p38, Jnk, and ERK1/2. Moreover, using vectors expressing dominant-negative forms of MyD88 and TRAF6, we established that LPS-induced activation of respiratory epithelial cells is largely dependent on TLR4 signaling intermediates. Altogether these data demonstrate that TLR4 is a key element in the response of pulmonary epithelial cells to molecules derived from Gram-negative bacteria. The intracellular localization of TLR4 in lung epithelia is expected to play an important role in the prevention of the development of chronic inflammatory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
9. Septin-dependent defense mechanisms against Pseudomonas aeruginosa are stalled in cystic fibrosis bronchial epithelial cells.
- Author
-
Brax, Sylvain, Gaudin, Clémence, Calmel, Claire, Boëlle, Pierre-Yves, Corvol, Harriet, Ruffin, Manon, and Guillot, Loïc
- Subjects
- *
EPITHELIAL cells , *CYSTIC fibrosis , *PSEUDOMONAS aeruginosa , *CYSTIC fibrosis transmembrane conductance regulator , *IMMUNE response , *LUNGS , *RHINOVIRUSES - Abstract
Airway epithelial cells form a physical barrier against inhaled pathogens and coordinate innate immune responses in the lungs. Bronchial cells in people with cystic fibrosis (pwCF) are colonized by Pseudomonas aeruginosa because of the accumulation of mucus in the lower airways and an altered immune response. This leads to chronic inflammation, lung tissue damage, and accelerated decline in lung function. Thus, identifying the molecular factors involved in the host response in the airways is crucial for developing new therapeutic strategies. The septin (SEPT) cytoskeleton is involved in tissue barrier integrity and anti-infective responses. SEPT7 is critical for maintaining SEPT complexes and for sensing pathogenic microbes. In the lungs, SEPT7 may be involved in the epithelial barrier resistance to infection; however, its role in cystic fibrosis (CF) P. aeruginosa infection is unknown. This study aimed to investigate the role of SEPT7 in controlling P. aeruginosa infection in bronchial epithelial cells, particularly in CF. The study findings showed that SEPT7 encages P. aeruginosa in bronchial epithelial cells and its inhibition downregulates the expression of other SEPTs. In addition, P. aeruginosa does not regulate SEPT7 expression. Finally, we found that inhibiting SEPT7 expression in bronchial epithelial cells (BEAS-2B 16HBE14o- and primary cells) resulted in higher levels of internalized P. aeruginosa and decreased IL-6 production during infection, suggesting a crucial role of SEPT7 in the host response against this bacterium. However, these effects were not observed in the CF cells (16HBE14o-/F508del and primary cells) which may explain the persistence of infection in pwCF. The study findings suggest the modification of SEPT7 expression as a potential approach for the anti-infective control of P. aeruginosa , particularly in CF. • SEPT7 inhibition reduced the expression of SEPT2, 6, 9, and 11 • SEPT7 encages intracellular P. aeruginosa in bronchial epithelial cells (BEC) • SEPT7 inhibition alters IL-6 levels in P. aeruginosa -infected BEC • SEPT7 inhibition further populates intracellular P. aeruginosa in CFTR sufficient BEC [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Glucocorticoids reduce inflammation in cystic fibrosis bronchial epithelial cells
- Author
-
Rebeyrol, Carine, Saint-Criq, Vinciane, Guillot, Loïc, Riffault, Laure, Corvol, Harriet, Chadelat, Katarina, Ray, David W., Clement, Annick, Tabary, Olivier, and Le Rouzic, Philippe
- Subjects
- *
CYSTIC fibrosis treatment , *GLUCOCORTICOIDS , *INFLAMMATION , *EPITHELIAL cells , *ANTI-inflammatory agents , *CELLULAR mechanics , *MITOGEN-activated protein kinases - Abstract
Abstract: Reduction of lung inflammation is one of the goals of cystic fibrosis (CF) therapy. Among anti-inflammatory molecules, glucocorticoids (GC) are one of the most prescribed. However, CF patients seem to be resistant to glucocorticoid treatment. Several molecular mechanisms that contribute to decrease anti-inflammatory effects of glucocorticoids have been identified in pulmonary diseases, but the molecular actions of glucocorticoids have never been studied in CF. In the cytoplasm, glucocorticoids bind to glucocorticoid receptor (GR) and then, control NF-κB and MAPK pathways through direct interaction with AP-1 and NF-κB in the nucleus. Conversely, MAPK can regulate glucocorticoid activation by targeting GR phosphorylation. Together these pathways regulate IL-8 release in the lung. Using bronchial epithelial cell lines derived from non CF and CF patients, we analyzed GR-based effects of glucocorticoids on NF-κB and MAPK pathways, after stimulation with TNF-α. We demonstrate that the synthetic glucocorticoid dexamethasone (Dex) significantly decreases IL-8 secretion, AP-1 and NF-κB activity in CF cells in a pro-inflammatory context. Moreover, we show that p38 MAPK controls IL-8 release by determining GR activation through specific phosphorylation on serine 211. Finally, we demonstrate a synergistic effect of dexamethasone treatment and inhibition of p38 MAPK inducing more than 90% inhibition of IL-8 production in CF cells. All together, these results demonstrate the good responsiveness to glucocorticoids of CF bronchial epithelial cells and the reciprocal link between glucocorticoids and p38 MAPK in the control of CF lung inflammation. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
11. Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells
- Author
-
Saint-Criq, Vinciane, Ruffin, Manon, Rebeyrol, Carine, Guillot, Loïc, Jacquot, Jacky, Clement, Annick, and Tabary, Olivier
- Subjects
- *
AZITHROMYCIN , *INFLAMMATION treatment , *CYSTIC fibrosis , *CHLORIDE channels , *EPITHELIAL cells , *GENETIC mutation , *NECROSIS , *TUMORS , *THERAPEUTICS - Abstract
Abstract: Cystic fibrosis is a hereditary disease caused by a mutation in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene that encodes a chloride (Cl-) channel. Cystic fibrosis pulmonary pathophysiology is characterised by chronic inflammation and bacterial infections. Azithromycin, a macrolide antibiotic, has shown promising anti-inflammatory properties in some inflammatory pulmonary diseases. Moreover, all clinical studies have presented an improvement of the respiratory condition of cystic fibrosis patients, but the molecular and cellular mechanisms remain unknown. The aim of this study was to investigate, in bronchial epithelial cells, the effects of azithromycin on inflammatory pathways involved in cystic fibrosis. We have analysed the effects of azithromycin on cystic fibrosis and non-cystic fibrosis bronchial epithelial cell lines but also in non-immortalized non-cystic fibrosis human glandular cells. To create an inflammatory context, cells were treated with Tumor Necrosis Factor (TNF)-α or Interleukin (IL)1-β. Activation of the NF-κB pathway was investigated by luciferase assay, western blotting, and by Förster Resonance Energy Transfer imaging, allowing the detection of the interaction between the transcription factor and its inhibitor in live cells. In all conditions tested, azithromycin did not have an anti-inflammatory effect on the cystic fibrosis human bronchial epithelial cells and on CFTR-inhibited primary human bronchial glandular cells. More, our data showed no effect of azithromycin on IL-1β– or TNF-α–induced IL-8 secretion and NF-κB pathway activation. Taken together, these data show that azithromycin is unable to decrease in vitro inflammation in cystic fibrosis cells from airways. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.